CD274 and neoplasm: Pembrolizumab was also approved for the treatment in patients with PD-L1-expressing NSCLC (Herbst et al., 2016; Reck et al., 2016) and increased expression of PD-L1 on tumor cells was associated with improved efficacy (Garon et al., 2015).